Welcome to our dedicated page for Arcturus Therape news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therape stock.
Arcturus Therapeutics Holdings Inc. (ARCT) is a clinical-stage RNA medicines company pioneering novel therapeutics and vaccines through its proprietary delivery platforms. This news hub provides investors and researchers with timely updates on the company's progress in developing self-amplifying mRNA (sa-mRNA) vaccines and rare disease treatments.
Access official press releases covering regulatory milestones, clinical trial developments, and strategic partnerships. Our curated collection includes updates on the LUNAR® delivery system's applications, STARR® mRNA technology advancements, and global collaborations like the ARCALIS joint venture in Japan.
Key updates include earnings reports, research publications, manufacturing expansions, and patent grants. Bookmark this page for direct access to primary source materials about ARCT's work in nucleic acid therapeutics, including programs targeting liver disorders, respiratory diseases, and infectious disease prevention.
For stakeholders tracking RNA medicine innovation, this repository offers organized chronological updates without promotional commentary. Check regularly for verified information about clinical-stage candidates and technology licensing agreements that demonstrate Arcturus' position in the biotechnology sector.
CSL and Arcturus Therapeutics announced results from a head-to-head study showing their self-amplifying mRNA (sa-mRNA) COVID-19 vaccine ARCT-154 maintained superior immunogenicity compared to Comirnaty® for up to one year. The study, presented at the OPTIONS XII conference, demonstrated:
1. Higher antibody levels against multiple SARS-CoV-2 strains, including Wuhan-Hu-1 and Omicron variants.
2. Effectiveness at one-sixth the dose of Comirnaty® (5 μg vs 30 μg).
3. Superior durability of immune response in both younger and older adults.
Additionally, their bivalent vaccine ARCT-2301 showed superior immunogenicity over Comirnaty® bivalent vaccine up to six months post-vaccination. The sa-mRNA platform vaccine targeting the JN.1 variant is now approved in Japan under the name KOSTAIVE®.
CSL (CSLLY) and Arcturus Therapeutics announced results from a head-to-head study showing their self-amplifying mRNA (sa-mRNA) COVID-19 vaccine maintained superior immunogenicity compared to Comirnaty® for up to one year. The study, presented at the OPTIONS XII conference, demonstrated ARCT-154 elicited superior antibody persistence against multiple SARS-CoV-2 strains at one-sixth the dose of Comirnaty®.
Key findings include:
- ARCT-154 showed superior neutralizing antibodies against Wuhan-Hu-1 strain at Day 361
- Similar advantages were observed against Omicron BA.4-5 and other variants
- A bivalent formula, ARCT-2301, also demonstrated superior immunogenicity over Comirnaty®
The sa-mRNA COVID-19 vaccine is approved in Japan under the name KOSTAIVE® for adults 18 and older.
CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics announced that Japan's Ministry of Health, Labor and Welfare has approved their updated self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, KOSTAIVE®, for adults 18 and older. The vaccine is tailored to protect against the JN.1 lineage of Omicron subvariants. Meiji Seika Pharma, CSL's exclusive partner in Japan, will distribute the vaccine for the October COVID-19 vaccination campaign.
KOSTAIVE® is the world's first commercially available sa-mRNA COVID-19 vaccine. Clinical evidence supports its safety and effectiveness, with data showing superior immunogenicity to Omicron BA 4/5 compared to conventional mRNA vaccines and immunity lasting up to one year. This approval aligns with recent World Health Organization recommendations and demonstrates CSL and Arcturus' commitment to innovative vaccine technology for viral respiratory diseases.
CSL and Arcturus Therapeutics announced that Japan's Ministry of Health, Labor and Welfare has approved their updated self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, KOSTAIVE®, for adults 18 and older. The vaccine is tailored to protect against the JN.1 lineage of Omicron subvariants. Meiji Seika Pharma, CSL's exclusive partner in Japan, will distribute the vaccine for the October 2024 vaccination campaign.
KOSTAIVE® is the world's first commercially available sa-mRNA COVID-19 vaccine for adults. Clinical data showed superior immunogenicity to Omicron BA 4/5 compared to conventional mRNA vaccines and immunity lasting up to one year. This approval aligns with recent World Health Organization recommendations and demonstrates CSL and Arcturus' commitment to innovative vaccine technology for viral respiratory diseases.
Arcturus Therapeutics (Nasdaq: ARCT) has received FDA clearance for its Investigational New Drug (IND) application for ARCT-032, an inhaled mRNA therapeutic for cystic fibrosis (CF). This clearance allows Arcturus to initiate a Phase 2 multiple ascending dose study to evaluate the safety, tolerability, and efficacy of ARCT-032 in CF patients. The study will focus on individuals who do not qualify for or benefit from CFTR modulator therapy.
Dr. Juergen Froehlich, Chief Medical Officer of Arcturus, stated that this development provides an opportunity to further validate their LUNAR® technology for delivering mRNA via inhalation. The study will assess ARCT-032 administered over several weeks at multiple dose levels in CF patients.
Arcturus Therapeutics Holdings Inc. (ARCT), a global mRNA medicines company, has announced its participation in several upcoming investor and scientific conferences in September 2024. These include:
- Wells Fargo 2024 Healthcare Conference (Fireside Chat) on September 4
- RNA Leaders USA Conference (Presentation) on September 5
- H.C. Wainwright 26th Annual Global Investment Conference (Presentation) on September 9
- Cantor Fitzgerald Annual Healthcare Conference (Fireside Chat) on September 18
Arcturus focuses on developing infectious disease vaccines and addressing unmet medical needs in liver and respiratory rare diseases. Investors can access webcast links for these events through the Investor Relations/Events section of the company's website.
Arcturus Therapeutics (ARCT) announced its Q2 2024 financial results and pipeline progress. Key highlights include:
1. IND submitted for Phase 2 trial of ARCT-032 for cystic fibrosis
2. ARCT-810 (OTC deficiency) Phase 2 interim data expected in Q4
3. Kostaive® on track for Q4 commercial launch in Japan
4. Q2 revenue of $49.9 million, up from $10.5 million in Q2 2023
5. Net loss of $17.2 million ($0.64 per share) compared to $52.6 million ($1.98 per share) in Q2 2023
6. Cash position of $317.2 million as of June 30, 2024
The company's pipeline progress and financial results demonstrate continued advancement in mRNA therapeutics and a strengthened financial position.
Arcturus Therapeutics Holdings (Nasdaq: ARCT), a global mRNA medicines company, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The event is scheduled for Tuesday, August 13, 2024, at 9:30 am Eastern Time in Boston. Arcturus specializes in developing infectious disease vaccines and treatments for liver and respiratory rare diseases.
Investors and interested parties can access a webcast and replay of Arcturus' presentation through the company's website. The presentation will be available in the 'Investor Relations/Events' section at https://ir.arcturusrx.com/investor-calendar. This conference appearance provides an opportunity for Arcturus to showcase its progress and potential to a wider audience of growth-oriented investors.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a global mRNA medicines company, has announced it will release its financial results for the second quarter of 2024 after the market close on Monday, August 5, 2024. The company will also host a conference call and webcast at 4:30 pm Eastern Time on the same day to discuss the results.
Arcturus focuses on developing infectious disease vaccines and medicines for liver and respiratory rare diseases. Investors and interested parties can join the earnings call using the provided domestic and international phone numbers or access the webcast through the company's website.
Arcturus Therapeutics (ARCT), a company specializing in mRNA medicines, provided updates on its ARCT-810 and ARCT-032 programs. The ARCT-810 Phase 2 study for OTC deficiency completed enrollment in Europe, with data expected later this year. This program is expanding in the U.S. to include more severely affected patients. ARCT-032, aimed at treating cystic fibrosis (CF), will submit an IND for a Phase 2 multiple ascending dose study within 60 days, based on positive safety data from previous trials. Key updates include the completion of subject enrollment in Europe for ARCT-810, the expansion of this program in the U.S., and promising preliminary results for ARCT-032 in treating CF patients.
FAQ
What is the current stock price of Arcturus Therape (ARCT)?
What is the market cap of Arcturus Therape (ARCT)?
